are sensitive to NMD in primary AML. Consequently, these AML cases do not express the predicted truncated WT1 proteins. In these AML cases, mutations in WT1 may result in haploinsufficiency rather than expression of truncated WT1 proteins with impaired function. Haploinsufficiency and impaired function have been proposed as two possible mechanisms by which mutant WT1 may affect normal hematopoietic development. Surprisingly, in the WT1 mutant AML cases the wild-type WT1 protein is expressed at relatively high levels. Although, this phenomena has been shown in sporadic Wilms' tumors and some related syndromes, it is currently unclear whether the WT1 protein is pathogenic in these cases or whether it is related to the etiology of the cell of origin.
Dasatinib is a US Food and Drug Administration-approved compound that was developed as an inhibitor of ABL and Src family kinases (SFKs). 1 Dasatinib is substantially more potent than imatinib against wild-type BCR-ABL. Moreover, with the exception of the T315I mutant, dasatinib retains activity against most imatinib-resistant BCR-ABL mutants, helping to explain the effectiveness of dasatinib in all stages of imatinib-resistant CML. The efficacy of dasatinib in CML is furthered by the ability of this compound to inhibit the SFK member LYN, which is persistently hyperactivated in imatinib-resistant disease. 2 Recent studies have revealed dasatinib effects on hematopoietic cells other than CML, and have suggested additional therapeutic opportunities, as well as adverse toxicities. Dasatinib inhibits the production of osteoclasts and tumor-associated macrophages, as well as the functional activities of osteoclasts, platelets, T cells and natural killer cells. [3] [4] [5] [6] [7] As these cell types do not express BCR-ABL, inhibition of SFK members such as LYN, or other kinase targets, is likely responsible for the effects of dasatinib on these cells.
Overexpression and/or hyperactivation of SFKs is common in acute myeloid leukemia (AML), but the impact of dasatinib on this disease is largely unknown. AML is a diverse malignancy characterized by defective myeloid differentiation and the accumulation of proliferative blasts. One subtype of AML, acute promyelocytic leukemia (APL), undergoes differentiation in response to treatment with all-trans retinoic acid (ATRA), and the combination of ATRA and chemotherapy results in a high cure rate in this disease. However, the other subtypes of AML, representing the majority of AML cases, are largely unresponsive to ATRA differentiation therapy. We have previously shown that SFKs can negatively regulate myeloid differentiation. 8 In this report, we sought to determine whether treatment of AML cell lines and primary cells with dasatinib might restore or enhance ATRA-induced differentiation.
To determine the impact of dasatinib treatment on myeloid differentiation, HL-60 and NB4 cells were incubated with dasatinib in the presence or absence of ATRA, followed by flow cytometric analysis of the myeloid differentiation marker CD11b (Figures 1a and b) . HL-60 cells were derived from a patient with AML (FAB M2), and NB4 from a patient with APL (FAB M3). Both undergo granulocytic differentiation when cultured in ATRA. To determine whether dasatinib would enhance ATRA-induced differentiation in these cell-line models, we used ATRA doses that yielded only low levels of differentiation in a 72-h assay (1 mM for HL-60; 0.01 mM for NB4; Figures 1a and b, data not shown). Dasatinib was used at doses (100, 500 nM and
not alter cell viability (not shown). Figures 1a
Letters to the Editor and b show that treatment with dasatinib alone did not promote differentiation. By contrast, co-treatment with dasatinib and ATRA for 72 h resulted in marked induction of CD11b expression, relative to that seen with ATRA or dasatinib alone. Enhancement of ATRA-induced differentiation was seen using dasatinib concentrations as low as 100 nM. Qualitatively and quantitatively similar results were seen when differentiation was scored by cytochemical staining with nitroblue tetrazolium (Supplementary Table 1) .
To investigate whether dasatinib could be used to restore ATRA-induced differentiation in primary AML cells representing a non-APL subtype, we treated leukemic blasts from a patient diagnosed with AML FAB M5 subtype ( Figure 1c) . As shown, cotreatment with dasatinib and ATRA resulted in enhanced differentiation relative to treatment with either agent alone. These findings suggest that FDA-approved dasatinib in combination with ATRA may provide therapeutic benefit in the treatment of non-APL AML, wherein current chemotherapy regimens are associated with considerable adverse toxicities and only modest improvement in survival outcomes.
Our findings are consistent with recent findings that the tyrosine-kinase inhibitors gefitinib and erlotinib can be used to promote myeloid differentiation.
9-11 Impressively, treatment of NSCLC patients harboring concomitant AML with the EGFR inhibitor erlotinib has been shown to result in complete remission of the AML. 12, 13 The effects of gefitinib and erlotinib on AML seem to be due to off-target effects on other tyrosine kinases, possibly SFKs, because AML cells do not express EGF receptors. We propose that similar therapeutic activity against AML might be achieved using dasatinib/ATRA combination.
SFKs are key targets of dasatinib and are overexpressed and/or hyperactivated in a majority of AML specimens. Immunoblotting for total protein levels revealed that HL-60 and NB4 cells expressed the SFK members LCK, LYN, FYN, HCK and c-SRC, whereas primary AML (FAB M5) cells expressed LCK, LYN and HCK (data not shown). To determine which of these SFKs were present in active form, we performed immunodepletion studies in which specific SFKs were immunoprecipitated from cell lysates, followed by immunoblotting with an antibody (a-phosphoSRC Y418) that recognizes the phosphorylated/ activated form of multiple SFK members. These experiments showed that immunodepletion of LYN resulted in nearly complete removal of the phosphorylated/activated SFKs from lysates of HL-60 and NB4 cells (Figures 2a and c) , as well as primary AML cells (Supplementary Figure 1) . In conjunction, phosphorylated/activated enzymes were detected only in the LYN immunoprecipitate pellet (Figures 2b and d) . These results indicate that LYN is the predominant activated SFK in the HL-60, NB4 and primary AML cells studied, and are consistent with the recent observation by Dos Santos et al.
14 pointing to the predominant activation of LYN in AML cells. These findings also raise the possibility that selective targeting of LYN may be useful for optimizing ATRA-induced differentiation, providing further refinement and impact to our discovery that treatment with dasatinib can enhance ATRA-stimulated differentiation in AML. 
